Proton pump inhibitor therapy use does not predispose to small intestinal bacterial overgrowth

American Journal of Gastroenterology

Volumn 107, Issue 5, 2012, Pages 730-735

  Ratuapli, Shiva K ^a   Ellington, Taylor G ^a   O'Neill, Mary Teresa ^a   Umar, Sarah B ^a   Harris, Lucinda A ^a   Foxx Orenstein, Amy E ^a   Burdick, George E ^a   DiBaise, John K ^a   Lacy, Brian E ^b   Crowell, Michael D ^a  

^a MAYO CLINIC   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROGEN; METHANE; PROTON PUMP INHIBITOR; GLUCOSE;

ADULT; ANTIDIARRHEAL ACTIVITY; ARTICLE; BACTERIAL OVERGROWTH; BREATHING; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HUMAN; INGESTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RISK; SMALL INTESTINE DISEASE; BLIND LOOP SYNDROME; BREATH ANALYSIS; CHEMICALLY INDUCED DISORDER; MICROBIOLOGY; MIDDLE AGED; SMALL INTESTINE;

BLIND LOOP SYNDROME; BREATH TESTS; FEMALE; GLUCOSE; HUMANS; HYDROGEN; INTESTINE, SMALL; MALE; METHANE; MIDDLE AGED; PROTON PUMP INHIBITORS;

EID: 84862339507     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2012.4     Document Type: Article

References (33)

1. Dukowicz AC, Lacy BE, Levine GM. Small intestinal bacterial overgrowth: a comprehensive review. Gastroenterol Hepatol 2007;3:112-22. (Pubitemid 46712476)
2. DiBaise JK. Nutritional consequences of small intestinal bacterial overgrowth. Pract Gastroenterol 2008;32:15-28.
3. Fine D, Schiller L. American Gastroenterological Association medical position statement: guidelines for the evaluation and management of chronic diarrhea. Gastroenterology 1999;116:1461-3.
4. Stotzer PO, Bjornsson ES, Abrahamsson H. Interdigestive and postprandial motility in small-intestinal bacterial overgrowth. Scand J Gastroenterol 1996;31:875-80. (Pubitemid 26313428)
5. Castiglione F, Del Vecchio Blanco G, Rispo A et al. Orocecal transit time and bacterial overgrowth in patients with Crohn's disease. J Clin Gastroenterol 2000;31:63-6. (Pubitemid 30430250)
6. McLoughlin GA, Hede JE, Temple JG et al. The role of IgA in the prevention of bacterial colonization of the jejunum in the vagotomized subject. Br J Surg 1978;65:435-7. (Pubitemid 8348973)
7. Husebye E, Skar V, Hoverstad T et al. Fasting hypochlorhydria with gram positive gastric flora is highly prevalent in healthy old people. Gut 1992;33:1331-7.
8. Th omson AB, Sauve MD, Kassam N et al. Safety of the long-term use of proton pump inhibitors. WJG 2010;16:2323-30.
9. Trikudanathan G, Israel J, Cappa J e t al. Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients - a systematic review and meta-analysis. Int J Clin Pract 2011;65:674-8.
10. McCarthy DM. Adverse effects of proton pump inhibitor drugs: clues and conclusions. Curr Opin Gastroenterol 2010;26:624-31.
11. Bajaj JS, Tannous M, Bootwala Z et al. Proton pump inhibitor use is associated with the development of a broad range of infections in cirrhosis. J Hepatol 2010;52:S66.
12. Friis-Hansen L. Achlorhydria is associated with gastric microbial overgrowth and development of cancer: Lessons learned from the gastrin knockout mouse. Scand J Clin Lab Invest 2006;66:607-22. (Pubitemid 44764395)
13. Vaezi MF. Risk of infection with PPI therapy. Gastroenterol Hepatol 2011;7:10-2.
14. Compare D, Pica L, Rocco A et al. Effects of long-term PPI treatment on producing bowel symptoms and SIBO. Eur J Clin Invest 2011;41:380-6.
15. Lombardo L, Foti M, Ruggia O et al. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2010;8:504-8.
16. Law D, Pimentel M. Proton pump inhibitor therapy does not affect hydrogen production on lactulose breath test in subjects with IBS. Digest Dis Sci 2010;55:2302-8.
17. Hutchinson S, Logan R. The effect of long-term omeprazole on the glucosehydrogen breath test in elderly patients. Age Ageing 1997;26:87-9. (Pubitemid 27241282)
18. Th orens J, Froehlich F, Schwizer W et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut 1996;39:54-9.
19. Fried M, Siegrist H, Frei R et al. Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. Gut 1994;35:23-6. (Pubitemid 24059466)
20. Saad RJ, Chey WD. Breath tests for gastrointestinal disease: the real deal or just a lot of hot air? Gastroenterology 2007;133:1763-6. (Pubitemid 350180840)
21. Posserud I, Stotzer PO, Bjornsson ES et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 2007;56:802-8. (Pubitemid 46854194)
22. Simren M, Stotzer PO. Use and abuse of hydrogen breath tests. Gut 2006;55:297-303. (Pubitemid 43268261)
23. Choung RS, Ruff KC, Malhotra A et al. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. Aliment Pharmacol Therapeut 2011;33:1059-67.
24. Lay C, Rigottier-Gois L, Holmstrom K et al. Colonic microbiota signatures across five northern European countries. Appl Environ Microbiol 2005;71:4153-5. (Pubitemid 40980596)
25. Mueller S, Saunier K, Hanisch C et al. Differences in fecal microbiota in different European study populations in relation to age, gender, and country: a cross-sectional study. Appl Environ Microbiol 2006;72:1027-33. (Pubitemid 43271206)
26. Singh VV, Toskes PP. Small bowel bacterial overgrowth: Presentation, diagnosis, and treatment. Curr Treat Options Gastroenterol 2004;7:19-28. (Pubitemid 38923716)
27. 2-breath testing in gastrointestinal diseases: the Rome Consensus Conference. Aliment Pharmacol Therapeut 2009;29 (Suppl 1):1-49.
28. Lewis SJ, Franco S, Young G et al. Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharmacol Therapeut 1996;10:557-61. (Pubitemid 26254799)
29. Pereira SP, Gainsborough N, Dowling RH. Drug-induced hypochlorhydria causes high duodenal bacterial counts in the elderly. Aliment Pharmacol Therapeut 1998;12:99-104. (Pubitemid 28057411)
30. Naylor G, Axon A. Role of bacterial overgrowth in the stomach as an additional risk factor for gastritis. Can J Gastroenterol 2003;17 (Suppl B):13B-7B.
31. Gasiorowska A, Navarro-Rodriguez T, Wendel C et al. Comparison of the degree of duodenogastroesophageal reflux and acid reflux between patients who failed to respond and those who were successfully treated with a proton pump inhibitor once daily. Am J Gastroenterol 2009;104:2005-13.
32. Williams C, McColl KEL. Review article: proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Therapeut 2006;23:3-10. (Pubitemid 43381161)
33. Limbachiya MS, Pande AH. Peptide derived from the lipid binding domain of Group IB human pancreatic phospholipase A(2) possesses antibacterial activity. Biochimie 2009;91:1387-93.